ARNI联合瑞舒伐他汀钙治疗心房颤动合并HFpEF患者的可行性研究  

Feasibility Study of ARNI Combined with Rosuvastatin Calcium in the Treatment of Patients with Atrial Fibrillation Combined with HFpEF

作　　者：韦伟 熊小奇[1] 李冰 WEI Wei;XIONG Xiaoqi;LI Bing(Liuzhou Liutie Central Hospital,Liuzhou 545007,China;不详)

机构地区：[1]柳州市柳铁中心医院,广西柳州545007

出　　处：《中外医学研究》2025年第4期17-20,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:研究血管紧张素受体脑啡肽酶抑制剂(angiotensin receptor-neprilysin inhibitor,ARNI)联合瑞舒伐他汀钙治疗心房颤动(简称房颤,atrial fibrillation,AF)合并射血分数保留心力衰竭(heart failure with preserved ejection fraction,HFpEF)患者的可行性。方法:选取2021年8月—2023年8月柳州市柳铁中心医院心内科收治的116例AF合并HFpEF患者作为研究对象,将其以电脑编号奇偶数字法随机分为A组(n=58)与B组(n=58)。所有患者均开展抗凝、吸氧等治疗,B组增用瑞舒伐他汀钙治疗,A组则增用ARNI联合瑞舒伐他汀钙治疗,对比两组疗效、心功能、心肌损伤指标及不良反应。结果:A组总有效率高于B组,差异有统计学意义(P<0.05);治疗6个月后,两组各项心功能指标较治疗前改善,且A组改善幅度较B组更大,差异有统计学意义(P<0.05);治疗6个月后,两组各项心肌损伤指标较治疗前降低,且A组较B组更低,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:ARNI联合瑞舒伐他汀钙治疗AF合并HFpEF患者可行性较佳,有利于患者心功能的改善,且不会增加不良反应的发生风险。Objective:To investigate the feasibility of angiotensin receptor-neprilysin inhibitor(ARNI)combined with Rosuvastatin Calcium in the treatment of patients with atrial fibrillation(AF)combined with heart failure with preserved ejection fraction(HFpEF).Method:A total of 116 patients with AF combined with HFpEF who admitted to the Department of Cardiology of Liuzhou Liutie Central Hospital from August 2021 to August 2023 were selected as the study objects,they were randomly divided into group A(n=58)and Group B(n=58)using the computer number method of odd and parity numbers.All the patients were treated with anticoagulation and oxygen inhalation,group B was additionally treated with Rosuvastatin Calcium,and group A was additionally treated with ARNI combined with Rosuvastatin Calcium,the efficacy,cardiac function,myocardial injury indexes and adverse reactions of two groups were compared.Result:The total effective rate of group A was higher than that of group B,the difference was statistically significant(P<0.05);after 6 months of treatment,the levels of cardiac function indexes in two groups were improved compared with those before treatment,and the improvement in group A were greater than those in group B,the differences were statistically significant(P<0.05);after 6 months of treatment,myocardial injury indexes in two groups were lower than those before treatment,and those in group A were lower than those in group B,the differences were statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:ARNI combined with Rosuvastatin Calcium is feasible in the treatment of patients with AF combined with HFpEF,which is conducive to the improvement of cardiac function and does not increase the risk of adverse reactions.

关 键 词：心房颤动 射血分数保留心力衰竭 血管紧张素受体脑啡肽酶抑制剂 瑞舒伐他汀钙 可行性 

分 类 号：R541.75[医药卫生—心血管疾病] R541.6[医药卫生—内科学]